Identification of a Novel Prognostic Signature for Gastric Cancer Based on Multiple Level Integration and Global Network Optimization.
competing endogenous RNAs
gastric cancer
integrated analysis
prognostic signature
random walk algorithm
Journal
Frontiers in cell and developmental biology
ISSN: 2296-634X
Titre abrégé: Front Cell Dev Biol
Pays: Switzerland
ID NLM: 101630250
Informations de publication
Date de publication:
2021
2021
Historique:
received:
20
11
2020
accepted:
22
03
2021
entrez:
29
4
2021
pubmed:
30
4
2021
medline:
30
4
2021
Statut:
epublish
Résumé
Gastric Cancer (GC) is a common cancer worldwide with a high morbidity and mortality rate in Asia. Many prognostic signatures from genes and non-coding RNA (ncRNA) levels have been identified by high-throughput expression profiling for GC. To date, there have been no reports on integrated optimization analysis based on the GC global lncRNA-miRNA-mRNA network and the prognostic mechanism has not been studied. In the present work, a Gastric Cancer specific lncRNA-miRNA-mRNA regulatory network (GCsLMM) was constructed based on the ceRNA hypothesis by combining miRNA-target interactions and data on the expression of GC. To mine for novel prognostic signatures associated with GC, we performed topological analysis, a random walk with restart algorithm, in the GCsLMM from three levels, miRNA-, mRNA-, and lncRNA-levels. We further obtained candidate prognostic signatures by calculating the integrated score and analyzed the robustness of these signatures by combination strategy. The biological roles of key candidate signatures were also explored. Finally, we targeted the PHF10 gene and analyzed the expression patterns of PHF10 in independent datasets. The findings of this study will improve our understanding of the competing endogenous RNA (ceRNA) regulatory mechanisms and further facilitate the discovery of novel prognostic biomarkers for GC clinical guidelines.
Identifiants
pubmed: 33912555
doi: 10.3389/fcell.2021.631534
pmc: PMC8072341
doi:
Types de publication
Journal Article
Langues
eng
Pagination
631534Informations de copyright
Copyright © 2021 Cui, Wang, Ning, Shao, Tan, Li, Zhong, Mi, Zhang and Jin.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Cancer Discov. 2011 Oct;1(5):391-407
pubmed: 22096659
Oncotarget. 2017 Aug 7;8(49):85463-85478
pubmed: 29156733
Oncotarget. 2018 Apr 6;9(26):18386-18399
pubmed: 29719612
Oncol Rep. 2019 Aug;42(2):615-628
pubmed: 31233188
J Integr Bioinform. 2019 Jul 13;16(3):
pubmed: 31301674
Cancers (Basel). 2014 Jul 07;6(3):1441-63
pubmed: 25003395
J Gastrointest Cancer. 2020 Jun 6;:
pubmed: 32504357
Sci Rep. 2017 Feb 16;7:42806
pubmed: 28202938
Mol Ther Oncolytics. 2018 Dec 31;12:173-194
pubmed: 30788428
Cell Mol Life Sci. 2019 Feb;76(3):495-504
pubmed: 30341461
Cancer Med. 2020 Jan;9(1):335-349
pubmed: 31743579
Biomed Res Int. 2015;2015:125094
pubmed: 25874201
Nat Commun. 2019 Mar 13;10(1):1197
pubmed: 30867426
Virchows Arch. 2014 Jul;465(1):25-33
pubmed: 24844205
Asian Pac J Cancer Prev. 2015;16(4):1361-5
pubmed: 25743799
J Cell Physiol. 2019 Aug;234(10):18065-18074
pubmed: 30963572
Genes Chromosomes Cancer. 2019 Apr;58(4):200-207
pubmed: 30350428
Cancer Lett. 2012 Jul 28;320(2):189-97
pubmed: 22388101
Int J Oncol. 2019 Jun;54(6):2157-2168
pubmed: 31081061
Cardiovasc Res. 2011 Jun 1;90(3):430-40
pubmed: 21558279
J Transl Med. 2018 Sep 27;16(1):264
pubmed: 30261893
BMC Res Notes. 2015 Nov 14;8:676
pubmed: 26576650
Onco Targets Ther. 2018 Dec 24;12:205-215
pubmed: 30636883
Front Oncol. 2020 Jun 19;10:565
pubmed: 32656071
Cancer Cell Int. 2019 May 7;19:123
pubmed: 31080364
J Cell Biochem. 2019 Nov;120(11):18845-18853
pubmed: 31338870
Transl Gastroenterol Hepatol. 2016 Apr 06;1:24
pubmed: 28138591
PLoS One. 2013 May 28;8(5):e64973
pubmed: 23724109
Onco Targets Ther. 2020 May 22;13:4533-4544
pubmed: 32547084
Gastric Cancer. 2016 Jan;19(1):107-15
pubmed: 25627474
Nat Rev Drug Discov. 2013 Nov;12(11):847-65
pubmed: 24172333
J Cell Biochem. 2020 Feb;121(2):1842-1854
pubmed: 31633246
BMB Rep. 2014 Jan;47(1):39-44
pubmed: 24209632
Eur Rev Med Pharmacol Sci. 2019 Jun;23(11):4756-4762
pubmed: 31210302
Mol Med Rep. 2013 Jan;7(1):229-32
pubmed: 23128435
Gastroenterol Res Pract. 2019 Dec 1;2019:9248394
pubmed: 31885548
Mol Cancer Ther. 2010 Jun;9(6):1764-74
pubmed: 20530714
World J Gastroenterol. 2008 Oct 21;14(39):5962-8
pubmed: 18932273
Cell Death Dis. 2020 Jul 9;11(7):521
pubmed: 32647147
Front Pharmacol. 2020 Jul 21;11:1112
pubmed: 32848739
Med Sci Monit. 2019 Aug 18;25:6313-6320
pubmed: 31422414
Trends Mol Med. 2018 Jan;24(1):66-84
pubmed: 29246760
Cells. 2020 Jun 28;9(7):
pubmed: 32605220
Cancer Biomark. 2018;23(3):437-445
pubmed: 30248047
Am J Hum Genet. 2008 Apr;82(4):949-58
pubmed: 18371930
Front Oncol. 2019 Nov 12;9:1212
pubmed: 31781506
Exp Ther Med. 2020 Mar;19(3):1997-2007
pubmed: 32104259
FEBS Lett. 2009 Nov 19;583(22):3725-30
pubmed: 19818772
Onco Targets Ther. 2020 Jan 20;13:559-571
pubmed: 32021298
Mol Cancer. 2016 Sep 20;15(1):60
pubmed: 27647437
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Genomics Proteomics Bioinformatics. 2016 Feb;14(1):42-54
pubmed: 26883671
Front Oncol. 2019 Nov 12;9:1243
pubmed: 31803620
Nat Rev Mol Cell Biol. 2018 Mar;19(3):143-157
pubmed: 29138516
Acta Biochim Biophys Sin (Shanghai). 2009 Aug;41(8):648-56
pubmed: 19657566
Cancer Sci. 2006 Apr;97(4):271-6
pubmed: 16630118
Mol Med Rep. 2018 Oct;18(4):3744-3750
pubmed: 30106095